GV contributed to the precision oncology platform developer's series A round, which will fund technology development and clinical studies.

US-based cancer analysis technology developer Xilis completed a $70m series A round yesterday featuring GV, a corporate venture capital subsidiary of internet and technology group Alphabet.

The Abu Dhabi state-owned Mubadala Capital led the round, which included LSP, Catalio Capital Management, Duke Endowment and Duke Angel Network, Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures and Alix Ventures.

Founded in 2019, Xilis is working on a precision oncology platform designed to help enhance cancer care and drug discovery and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn